- Home
- INMB vs VIGL Comparison
INMB vs VIGL Comparison
Compare INMB & VIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INMB
- VIGL
- Stock Information
- Founded
- INMB 2015
- VIGL 2020
- Country
- INMB United States
- VIGL United States
- Employees
- INMB N/A
- VIGL N/A
- Industry
- INMB Biotechnology: Pharmaceutical Preparations
- VIGL Biotechnology: Pharmaceutical Preparations
- Sector
- INMB Health Care
- VIGL Health Care
- Exchange
- INMB Nasdaq
- VIGL Nasdaq
- Market Cap
- INMB 68.9M
- VIGL 134.9M
- IPO Year
- INMB 2019
- VIGL 2022
- Fundamental
- Price
- INMB $2.07
- VIGL $8.07
- Analyst Decision
- INMB Buy
- VIGL Buy
- Analyst Count
- INMB 4
- VIGL 7
- Target Price
- INMB $9.53
- VIGL $8.00
- AVG Volume (30 Days)
- INMB 7.0M
- VIGL 798.1K
- Earning Date
- INMB 07-31-2025
- VIGL 08-12-2025
- Dividend Yield
- INMB N/A
- VIGL N/A
- EPS Growth
- INMB N/A
- VIGL N/A
- EPS
- INMB N/A
- VIGL N/A
- Revenue
- INMB $50,000.00
- VIGL N/A
- Revenue This Year
- INMB $82.14
- VIGL N/A
- Revenue Next Year
- INMB $28,750.98
- VIGL N/A
- P/E Ratio
- INMB N/A
- VIGL N/A
- Revenue Growth
- INMB N/A
- VIGL N/A
- 52 Week Low
- INMB $1.89
- VIGL $1.31
- 52 Week High
- INMB $11.64
- VIGL $8.11
- Technical
- Relative Strength Index (RSI)
- INMB 25.67
- VIGL 89.08
- Support Level
- INMB $2.22
- VIGL $8.03
- Resistance Level
- INMB $2.49
- VIGL $8.05
- Average True Range (ATR)
- INMB 0.85
- VIGL 0.03
- MACD
- INMB -0.13
- VIGL -0.12
- Stochastic Oscillator
- INMB 1.85
- VIGL 86.73
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a clinical-stage biotechnology company engaged in improving the lives of patients, caregivers, and families affected by rare and common neurodegenerative diseases by pursuing the development of disease-modifying therapeutics to restore the vigilance of microglia. Microglia are the sentinel immune cells of the brain and play a critical role in maintaining central nervous system (CNS) health and responding to damage caused by disease. The group provides solutions for fully human monoclonal antibody and Oral small molecule TERM2 agonist.